Inactive Instrument

Highlights Beigene Ltd Hong Kong S.E.

Equities

End-of-day quote Hong Kong S.E. Other stock markets
- ^HKD	-

Jul. 16	Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating	MT
Jul. 16	Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading	Jul. 12	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note	Jul. 01	MT
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	Jun. 14	MT
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	Jun. 14	CI
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	Jun. 12	CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	May. 28	MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	May. 28	MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	May. 28	CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	May. 24	MT
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	May. 24	CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India	May. 21	MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene	May. 20	CI
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024	May. 14	CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08	MT
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08	MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M	May. 08	MT
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08	CI
Amgen Posts Higher 1Q Revenue, Swings to Loss	May. 02	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Beigene Ltd Hong Kong S.E.

Equities

Highlights

Filters